The global impact of Alzheimer's disease (AD) continues to increase, and focused efforts are
needed to address this immense public health challenge. National leaders have set a goal …

Introduction Drugs that prevent the onset, slow progression, or improve cognitive and
behavioral symptoms of Alzheimer's disease (AD) are needed. Methods We searched …

Introduction Alzheimer's disease (AD) represents a global health crisis. Treatments are
needed to prevent, delay the onset, slow the progression, improve cognition, and reduce …

Alzheimer disease (AD) drug development has a high failure rate. Drug development
decision making can be improved based on lessons learned from past trials. Improved …

Alzheimer's disease (AD) has no currently approved disease-modifying therapies (DMTs),
and treatments to prevent, delay the onset, or slow the progression are urgently needed. A …

Introduction Alzheimer's disease (AD) is a growing public health concern affecting millions of
patients worldwide and costing billions of dollars annually. We review the pipeline of drugs …

Introduction Alzheimer's disease (AD) is increasing in frequency as the global population
ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors …

Abstract Introduction Treatments for Alzheimer's disease (AD) are needed due to the
growing number of individuals with preclinical, prodromal, and dementia forms of AD. Drug …

Introduction There is an urgent need to develop new treatments for Alzheimer's disease (AD)
and to understand the drug development process for new AD therapies. Methods We …

Introduction Alzheimer's disease (AD) has few available treatments, and there is a high rate
of failure in AD drug development programs. Study of the AD drug development pipeline can …